PHS was strongly associated with amyloid positivity and the combination of PHS and biomarker status significantly predicted longitudinal clinical progression.
ABSTRACT Background
There is an urgent need for the early identification of nondemented individuals at the highest risk of progressing to Alzheimer's disease (AD) dementia for early therapeutic interventions. Our goal was to evaluate whether a recently validated polygenic hazard score (PHS) can be integrated with known in vivo CSF or PET biomarkers of amyloid or tau pathology to prospectively predict cognitive decline and clinical progression to AD dementia in nondemented older individuals.
Methods
We evaluated 347 cognitive normal (CN) and 599 mild cognitively impaired (MCI) individuals.
We first investigated whether PHS can predict CSF or PET amyloid and tau deposition. We evaluated differences in positive and negative predictive values of biomarker status, as a function of PHS risk. Next, we used linear mixed-effects (LME) to examine if PHS and biomarker status in conjunction, best predict longitudinal cognitive and clinical progression. Lastly, we used survival analysis to investigate whether a combination of PHS and biomarker positivity predicts progression to AD dementia better than using PHS or biomarker positivity alone.
Findings
In CN and MCI individuals, we found that amyloid and total tau positivity systematically varies as a function of PHS. For individuals in greater than the 50 th percentile PHS, the positive predictive value for amyloid approached 100%. Similarly, for individuals in less than the 25 th percentile PHS, the negative predictive value for total tau approached 85%. Beyond APOE, high PHS individuals with amyloid and tau pathology showed the fastest rate of longitudinal cognitive decline and time to AD dementia progression. Among the CN subgroup, we similarly found that
INTRODUCTION
Accumulating genetic, molecular, biomarker and clinical evidence indicates that the pathobiological changes underlying late-onset Alzheimer's disease (AD) occur 20-30 years before the onset of clinical symptoms 1, 2 . AD associated pathology may follow a temporal sequence whereby β -amyloid dysmetabolism (i.e. assessed in vivo as reductions in CSF levels of Aβ or increase in PET 18 F-AV-45) precedes tau accumulation (i.e. assessed in vivo as elevations in CSF total tau) and neurodegeneration 3 However, the value of combining PHS with in vivo biomarkers of AD pathology to predict cognitive and clinical progression among nondemented older individuals remains unknown. Here, among MCI and CN individuals, we evaluated whether PHS can be useful as a marker for enriching and stratifying Alzheimer's associated amyloid and tau pathology.
METHODS

Participants and clinical characterization
We Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). We restricted analyses to CN individuals (n = 347) and patients diagnosed with MCI, (n = 599) who had both genetics and CSF or PET biomarkers (CSF Aβ 1-42 , CSF total tau, or PET 18 F-AV45) data. We used previously established thresholds of <192 pg/ml, >23 pg/ml 8 and >1.1 9 to indicate 'positivity' for CSF Aβ 1-42 , CSF total tau and PET 18 F-AV-45, respectively. We classified individuals as amyloid 'positive' if they reached either CSF Aβ 1-42 or PET 18 F-AV45 threshold for positivity, given that PET and CSF amyloid biomarkers provide highly correlated measurements of intracranial amyloid deposition 10 . Cohort demographics are summarized in Table 1 .
Polygenic hazard score (PHS)
For each CN and MCI participant in this study, we calculated their individual PHS, as previously described 6 . In brief, AD associated SNPs (at p < 10 -5 ) were first identified using genotype data 
Statistical analysis
Using logistic regression, we first evaluated the relationship between PHS and baseline amyloid and total tau positivity (binarized as positive or negative) in CN and MCI individuals. In these analyses, we controlled for age at baseline, sex, education, and APOE ε 4 status (binarized as having at least one copy of the ε 4 allele versus none). We further ascertained the 'enrichment' in amyloid and tau positive predictive value (PPV), and negative predictive value (NPV) for clinical progression to AD dementia, as a function of PHS percentiles.
Next, we used linear mixed-effects (LME) models in CN and MCI individuals to investigate whether a statistical interaction between PHS and amyloid or total tau status significantly predicted longitudinal cognitive decline and clinical progression (mean follow-up time = 2.36 years, SD = 1.99 years). We conducted LME models separately for amyloid and total tau. We defined cognitive decline using change scores in 2 domains, namely executive function and memory, based on composite scores developed using the ADNI neuropsychological battery and validated using confirmatory factor analysis 11 . We defined clinical progression using change scores in Cognitive Dementia Rating -Sum of Boxes (CDR-SB). We examined the main and interactive effects of PHS and biomarker positivity on cognitive decline and clinical progression rate while controlling for age, sex, education, APOE ε 4 status, using the following LME model:
Here, ∆ c = cognitive decline (executive function or memory) or clinical progression (CDR-SB) rate, ∆ t = change in time from baseline visit (years), biomarker_status = positive or negative for amyloid or total tau, and (1|subject) specifies the random intercept. We centered and scaled the continuous predictors (PHS and time) and covariates (age at baseline and education) prior to analysis. We were specifically interested in PHS × biomarker_status × ∆ t, whereby a significant interaction indicates differences in rates of decline, as a function of differences in PHS and biomarker status. We then examined the simple main effects by comparing slopes of cognitive decline and clinical progression over time for individuals who were biomarker positive or negative, and with either high (~84 percentile) or low PHS (~16 percentile). We defined high and low PHS by 1 standard deviation above or below the mean of PHS respectively 7 . To assess the added utility of PHS in predicting cognitive and clinical decline, we further compared the LME models with reduced LME models without PHS using likelihood ratio tests.
Using a survival analysis framework, we next investigated the value of combining PHS with amyloid and total tau biomarkers status to predict time to AD dementia progression.
Specifically, we examined the effects of 1) PHS, 2) PHS in individuals who were amyloid positive, and 3) PHS in individuals who were amyloid and total tau positive, on time to AD dementia progression using a Cox proportional hazards model. Age of AD dementia onset was used as the time to event. 'Ties' were resolved using the Breslow method. We co-varied for the effects of sex, education, APOE ε 4 status, age at baseline, and also age at baseline stratified into quintiles to adjust for violations of Cox proportional hazards assumptions by baseline age. We restricted survival analyses, which involves AD dementia censoring, as well as the PPV/NPV analyses (see above) to the combined CN and MCI groups only as the CN individuals had low conversion rates during the observation period (< 5%).
Finally, building on our prior work 6 , we assessed whether amyloid and tau status could inform PHS-predicted annualized incidence rate of AD age of onset. We examined the influence of amyloid status, total tau status, and both in combination on the PHS-derived annualized incidence rate of AD dementia age of onset, based on previously established AD incidence estimates from the United States population 12 .
RESULTS
PHS enriches AD predictive value of amyloid and tau deposition
Within the combined MCI and CN cohort, we found that PHS predicted amyloid (Odds ratio (OR) = 2·31, 95% Confidence Interval (CI) = 1·55 -3·49, p = 5·50×10 -5 ) and total tau (OR =1·87, 95% CI = 1·31 -2·68, p = 6·53×10 -4 ) positivity. As illustrated in Figure 1 , we found that the proportion of individuals who were amyloid or total tau positive increased systematically as a function of higher PHS. For example, approximately 60% of individuals in the 75 th PHS percentile would be classified as amyloid positive whereas less than 40% of individuals in the 25 th PHS percentile would be amyloid positive. In subgroup analyses involving only CN individuals, PHS predicted amyloid (OR = 2·44, 95% CI = 1·13 -5·55, p = 0·028) but not total tau (OR =1·53, 95% CI = 0·71 -3·35, p = 0·28) positivity. Within MCI individuals only, PHS predicted amyloid (OR = 1·96, 95% CI = 1·17 -3·33, p = 1·12×10 -2 ) and total tau (OR =2·24, 95% CI = 1·12 -4·59, p = 2·46×10 -2 ) positivity.
Similarly, within the combined MCI and CN cohort, we found that PPV of amyloid and total tau increased systematically as a function of higher PHS percentiles (Figure 2a ). For instance, the PPV for amyloid positivity approaches 100% amongst individuals with ≥ 50th
percentile PHS but for individuals in ≤ 25 th percentile PHS, amyloid PPV is approximately 75%.
Based on a 1000 bootstrap of 50 random samples, PPV for all individuals was higher for amyloid compared to total tau (Welch t-test, t (1339·1) = 137·92, p <2×10 -16 ). In contrast, we found that NPV was highest in individuals with low PHS percentiles, especially for total tau (Figure 2b) .
For amyloid and total tau, we note that the maximum absolute value PPV (approximately 98%) as a function of PHS was higher than the maximum absolute NPV (approximately 85%) as a function of PHS.
PHS enriches amyloid and tau associated prediction of clinical and cognitive decline
Using LME analyses within the combined MCI and CN cohort, we investigated the role of PHS in conjunction with amyloid and total tau positivity in predicting cognitive decline (executive function and memory) and clinical progression (i.e. increase in CDR-SB), and found that the 3-way interactions (PHS × biomarker_status × ∆ t) were statistically significant for amyloid in executive function (β = -0·14, SE = 0·02, p = 1·01×10 -13 ), memory (β = -0·05, SE = 0·02, p = 1·87×10 -3 ), CDR-SB: β = 0·55, SE = 0·06, p < 2×10 -16 ), and for total tau in executive function (β = -0·10, SE = 0·02, p = 1·39×10 -9 ), memory (β = -0·05, SE = 0.02, p =1·24×10 -3 ), and CDR-SB (β = 0·40, SE = 0·06, p = 2·35×10 -12 ). We conducted simple slopes analyses and found Supplementary Table 1, Figure 3 ).
In addition, using likelihood ratio tests, we found that these full LME models resulted in a better fit than a reduced, non-PHS model with only amyloid status (executive function: χ 2 (4) = 76·3, p = 1·07×10 -15 ; memory: χ 2 (4) = 34·3, p = 6·45×10 -7 ; CDR-SB:
or total tau status (executive function: χ 2 (4) = 56·3, p = 1·76×10 -11 ; memory: χ 2 (4) = 42·2, p = 1·54×10 -8 ; CDR-SB: χ 2 (1) = 113·11, p < 2×10 -16 ). Specifically, amyloid or total tau positive individuals with high PHS showed greater cognitive decline and faster clinical progression than individuals who were amyloid or total tau positive, regardless of PHS ( Figure 3 ). These findings demonstrate the added value of using PHS in conjunction with biomarker status to identify individuals who would experience the greatest rate of cognitive decline and clinical progression.
In CN subgroup analyses, the 3-way interaction was only significant for PHS and amyloid status in predicting change in CDR-SB (β = 0·16, SE = 0·07, p = 1·88×10 -2 ), but not executive function (β = -0·02, SE = 0·03, p = 0.42) and memory (β = 0·04, SE = 0.03, p = 0·11).
In simple main effects analysis for CDR-SB, high PHS and amyloid positive individuals also showed the greatest rate of progression (β = 0·60, SE = 0·13, p = 3·47×10 -6 ). For PHS with total tau status, the 3-way interaction was significant in predicting changes in executive function (β = -0·11, SE = 0·03, p = 5·77×10 -4 ) and CDR-SB (β = 0·30, SE = 0·08, p = 9·21×10 -5 ) but not memory (β = -0·03, SE = 0·03, p = 0·36). Similarly, in simple main effect analyses, high PHS and tau positive individuals showed the greatest rate of cognitive and clinical decline (executive function: β = -0·28, SE = 0·06, p = 7·26×10 -6 ; CDR-SB: β = 0·85, SE = 0·15, p = 4·18×10 -8 ).
In MCI subgroup analyses, the 3-way interaction was significant for PHS and amyloid status in predicting change in executive function (β = -0·14, SE = 0·02, p = 3·47×10 -9 ), memory (β = -0·08, SE = 0·02, p = 2·22×10 -4 ), and CDR-SB (β = 0·49, SE = 0.09, p = 2·29×10 -8 ). In simple main effect analysis, high PHS and amyloid positive individuals also showed the greatest rate of change for executive function (β = -0·51, SE = 0·04, p < 2×10 -16 ), memory (β = -0·42, SE = 0·04, p < 2×10 -16 ) and CDR-SB (β = 2·24, SE = 0·17, p < 2×10 -16 ). For PHS with total tau status, the 3-way interaction was significant in predicting changes in CDR-SB (β = 0·17, SE = 0·07, p = 1·94×10 -2 ) but not for executive function (β = -0·03, SE = 0·02, p = 0·14) and memory (β = -0·03, SE = 0·02, p = 0·11). In simple main effect analyses of the significant interaction, high PHS and tau positive individuals showed the greatest rate of clinical progression (CDR-SB: β = 2·25, SE = 0·17, p < 2×10 -16 ).
PHS enriches amyloid + tau prediction of time to AD dementia progression
We used Cox proportional hazards model to investigate clinical progression of nondemented individuals (CN + MCI) to AD dementia, and found that PHS predicted progression (Hazard ratio (HR) = 1·74, 95% CI = 1·30 -2·33, p = 2·26×10 -4 ). PHS also predicted progression when including amyloid status in the model (HR = 1·49, 95% CI = 1·11 -2·00, p = 8·06×10 -3 ), and when including both amyloid and total tau status in conjunction (HR = 1·44, 95% CI = 1·07 -1·94, p = 1·67×10 -2 ) (Figure 4 ). Comparing goodness of fit using likelihood ratio tests, we found that the reduced models involving only PHS (and covariates) were improved when including amyloid status (χ 2 (1) = 54·1, p = 1·94×10 -13 ), and both amyloid status and total tau status in conjunction (χ 2 (2) = 80·1, p < 2×10 -16 ). The combined model which included PHS, amyloid and total tau status showed the best fit and best predicted time to AD dementia progression than just amyloid and tau status (χ 2 (1) = 5·59, p = 1·81×10 -2 ).
Amyloid + tau positive individuals show highest PHS derived annualized AD incidence rates
Finally, we generated population baseline-corrected survival curves stratified by amyloid and total tau positivity status and converted them directly into incidence rates based on PHS 6 .
This measure of cumulative incidence rate (CIR) based on age and PHS provides the annualized risk of a nondemented individual for progressing to AD dementia. As illustrated in Figure 5 , we found that amyloid and total tau positive individuals showed the highest CIRs compared to other groups, particularly at later ages (over 80). An individual who tested negative for amyloid at baseline would have a CIR of 0.025 at age 70 and 0.37 at age 90. In contrast, an individual who tested positive for both amyloid and total tau at baseline would have a higher CIR of 0.075 at age 70, and 0.73 at age 90. These results indicate that amyloid and total tau positive individuals with high PHS risk will likely experience the highest annualized AD dementia incidence rates.
DISCUSSION
In this study, we show that the predictive value of Alzheimer's associated intracranial amyloid and tau deposition increases systematically as a function of PHS; for MCI and CN individuals in greater than the 50 th percentile PHS, the positive predictive value for amyloid approached 100%. Beyond APOE ε 4, by integrating PHS with in vivo biomarkers of AD pathology, we were able to identify nondemented older individuals at highest risk for AD dementia progression and with the steepest longitudinal cognitive decline. Crucially, the combination of PHS, amyloid and total tau best predicted time to AD dementia progression and cognitive decline further indicating the value of stratifying by PHS, beyond amyloid or total tau alone. Collectively, our findings indicate that among nondemented older individuals, PHS can serve as an 'enrichment' marker for AD associated intracranial amyloid and tau deposition.
From a clinical trial perspective, PHS may be useful in AD secondary prevention and therapeutic trials. Building on prior work 13, 14 , our PPV results indicate that PHS can be used to enrich clinical trial cohorts by identifying those nondemented individuals with amyloid or tau pathology who are at highest risk of progressing to AD dementia and therefore most likely to benefit from therapeutic intervention. As PHS strongly predicted both amyloid and total tau positivity, PHS may also serve as an initial screening tool for in vivo AD pathology; for cohort enrichment in trials, it may be helpful to pursue a stratified approach 15, 16 where costlier secondary assessments using CSF or PET biomarker assays are obtained only in those individuals with a high PHS. We note that the PPV was higher for amyloid compared to total tau indicating that PHS provides more enrichment in amyloid compared to tau pathology. In contrast, we found that NPV was highest in individuals with low PHS percentiles, especially for total tau, indicating that individuals who tested negative for total tau and had low PHS were very unlikely to progress to AD dementia subsequently.
From a clinical perspective, PHS may be useful for risk stratification of nondemented older individuals. In our linear mixed effects and survival analyses, we found that PHS considerably improved the ability of amyloid and tau to predict time to AD dementia progression and longitudinal cognitive decline. Importantly, the combination of PHS, amyloid and total tau best predicted clinical and cognitive decline. Together, these findings suggest that a PHSstratified approach may be clinically useful. Therefore, PHS can be useful as a first step for determining an older individual's genetic risk for AD dementia. Rather than evaluating all individuals, amyloid and tau assessments may be most helpful only in those individuals with a high PHS. Conversely, among individuals with a low PHS, it may be less effective to pursue additional evaluation with amyloid biomarkers.
Building on prior work evaluating polygenic risk in preclinical AD 17, 18, 19 our findings indicate that PHS may be useful for predicting clinical and cognitive decline among asymptomatic older individuals. Among CNs, we found that significant interactions between PHS and amyloid or tau predicted longitudinal change in CDR-SB. Furthermore, PHS predicted amyloid positivity even in CN individuals. Together, these results indicate that the utility of using PHS for cohort enrichment and pre-screening may extend into preclinical AD. In other words, PHS can identify cognitively asymptomatic individuals who are more likely to show AD pathology and who may be at highest risk for clinical progression over time.
In conclusion, we show the utility of integrating PHS with in vivo biomarkers of amyloid Low PHS/amyloid --0·17 (0·03) 2·09×10 -11 -0·14 (0·02) 1·09×10 -9 0·42 (0·09) 1·99×10 -6
High PHS/total tau + -0·46 (0·04) <2×10 -16 -0·38 (0·03) <2×10 -16 1·86 (0·13) <2×10 -16
High PHS/total tau --0·20 (0·04) 2·04×10 -7 -0·19 (0·03) 3·36×10 -8 0·69 (0·13) 1·34×10 -7
Low PHS/total tau + -0·22 (0·03) 6·86×10 -12 -0·22 (0·03) 9·33×10 -15 0·70 (0·11) 6·45×10 -11
Low PHS/total tau --0·16 (0·03) 1·30×10 -9 -0·13 (0·02) 8·49×10 -8 0·32 (0·10) 5·33×10 -4 CDR-SB: Cognitive dementia rating -Sum of boxes. Significant effects are in bold
